Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

29,819 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Han HQ, Zhou X, Mitch WE, Goldberg AL. Han HQ, et al. Among authors: zhou x. Int J Biochem Cell Biol. 2013 Oct;45(10):2333-47. doi: 10.1016/j.biocel.2013.05.019. Epub 2013 May 28. Int J Biochem Cell Biol. 2013. PMID: 23721881 Review.
Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease.
Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, Song Y, Min H, Wang X, Du J, Mitch WE. Zhang L, et al. Among authors: zhou x. FASEB J. 2011 May;25(5):1653-63. doi: 10.1096/fj.10-176917. Epub 2011 Jan 31. FASEB J. 2011. PMID: 21282204 Free PMC article.
Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
Toledo M, Busquets S, Penna F, Zhou X, Marmonti E, Betancourt A, Massa D, López-Soriano FJ, Han HQ, Argilés JM. Toledo M, et al. Among authors: zhou x. Int J Cancer. 2016 Apr 15;138(8):2021-9. doi: 10.1002/ijc.29930. Epub 2015 Dec 9. Int J Cancer. 2016. PMID: 26595367
Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia.
Kwak KS, Zhou X, Solomon V, Baracos VE, Davis J, Bannon AW, Boyle WJ, Lacey DL, Han HQ. Kwak KS, et al. Among authors: zhou x. Cancer Res. 2004 Nov 15;64(22):8193-8. doi: 10.1158/0008-5472.CAN-04-2102. Cancer Res. 2004. PMID: 15548684
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ. Zhou X, et al. Cell. 2010 Aug 20;142(4):531-43. doi: 10.1016/j.cell.2010.07.011. Cell. 2010. PMID: 20723755
miR‑181b‑5p inhibits trophoblast cell migration and invasion through targeting S1PR1 in multiple abnormal trophoblast invasion‑related events.
Miao J, Zhu Y, Xu L, Huang X, Zhou X. Miao J, et al. Among authors: zhou x. Mol Med Rep. 2020 Nov;22(5):4442-4451. doi: 10.3892/mmr.2020.11515. Epub 2020 Sep 17. Mol Med Rep. 2020. PMID: 33000224
Neuropeptide Y upregulates Runx2 and osterix and enhances osteogenesis in mouse MC3T3‑E1 cells via an autocrine mechanism.
Zhang B, Zhang X, Xiao J, Zhou X, Chen Y, Gao C. Zhang B, et al. Among authors: zhou x. Mol Med Rep. 2020 Nov;22(5):4376-4382. doi: 10.3892/mmr.2020.11506. Epub 2020 Sep 14. Mol Med Rep. 2020. PMID: 33000198
miR‑155‑5p downregulation inhibits epithelial‑to‑mesenchymal transition by targeting SIRT1 in human nasal epithelial cells.
Yang N, Cheng H, Mo Q, Zhou X, Xie M. Yang N, et al. Among authors: zhou x. Mol Med Rep. 2020 Nov;22(5):3695-3704. doi: 10.3892/mmr.2020.11468. Epub 2020 Aug 27. Mol Med Rep. 2020. PMID: 33000196
PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy.
Qin Y, Jiang L, Yu M, Li Y, Zhou X, Wang Y, Gong Y, Peng F, Zhu J, Liu Y, Xu Y, Zhou L, Lu Y, Huang M. Qin Y, et al. Among authors: zhou x. Sci Rep. 2020 Sep 30;10(1):16150. doi: 10.1038/s41598-020-73013-3. Sci Rep. 2020. PMID: 32999345
29,819 results
Jump to page